AP 214 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses AP 214 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Action Pharma A/S (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AP 214 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac SurgeryCompletedPhase 2Action Pharma A/SNCT01256372Written as AP214
- Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac SurgeryCompletedPhase 2Action Pharma A/SNCT00903604Written as AP214
- Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac SurgeryTerminatedPhase 2Action Pharma A/SNCT00628264Written as AP214